Neurometabolic therapy as a means of secondary prophylaxis of stroke

Author:
V.V. KOVALCHUK

St. Petersburg GBUZ City Hospital No. 38 named after N.A. Semashko, St. Petersburg

Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 3, 2014

Abstract:
The aim of the study was to analyze the efficacy of Mexidol in the secondary prevention of ischemic stroke (IS). Material and Methods. The analysis included treatment outcomes in 3,400 patients who had suffered IS and were divided into 7 groups: patients with cryptogenic IS, hypertension, atrial fibrillation, metabolic syndrome, obstructive sleep apnea/hypnea syndrome, diabetes mellitus, and vasculitis. Treatment efficacy was assessed based on the absence of recurrent IS within 5 years of therapy. Results. Mexidol reduces the incidence of recurrent IS both in patients without comorbidities and in patients with hypertension, obstructive sleep apnea/hypnea syndrome, vasculitis, diabetes mellitus, atrial fibrillation, and metabolic syndrome. Conclusion. Further studies of the efficacy of Mexidol in the secondary prevention of IS appear promising. Key words: stroke, secondary prevention, mexidol.

Actual

Actual

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com